Martin Hutchings, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, discusses the results from a Phase I/II dose-escalation study investigating subcutaneous epcoritamab (CD3xCD20) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Additionally, Dr Hutchings outlines safety signals detected during the clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
|
|
|
